Cardiol Therapeutics
CRDL
27 hedge funds and large institutions have $6.98M invested in Cardiol Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.
0.15% less ownership
Funds ownership: 8.7% → 8.56% (-0.15%)
4% less funds holding
Funds holding: 28 → 27 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
16% less capital invested
Capital invested by funds: $8.27M → $6.98M (-$1.29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$142K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$27.2K |
| 3 |
BCM
Brookstone Capital Management
Wheaton,
Illinois
|
+$21.4K |
| 4 |
LPL Financial
San Diego,
California
|
+$14.6K |
| 5 |
MOS
MGO One Seven
Beachwood,
Ohio
|
+$14.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$100K |
| 2 |
Jane Street
New York
|
-$57K |
| 3 |
Two Sigma Advisers
New York
|
-$52.4K |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$45.9K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$32.4K |
CRDL Hedge Fund Activity: Q2 2022 in Review
27 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q2 2022, worth a combined $6.98M — down 16% from $8.27M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CRDL and 6 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 6 added.
The largest buyer was MMCAP International, adding an estimated $142K. The largest seller was Goldman Sachs, exiting entirely with an estimated $100K sold.
- 27 institutional investors held Cardiol Therapeutics (CRDL) as of Q2 2022, down from 28 in Q1 2022.
- Funds reported $6.98M of Cardiol Therapeutics stock for Q2 2022, down 16% quarter-over-quarter.
- 6 funds opened new Cardiol Therapeutics positions in Q2 2022 and 7 closed out, a net change of -1 holder.
- The largest Cardiol Therapeutics buyer in Q2 2022 was MMCAP International, an estimated $142K added.
- The largest Cardiol Therapeutics seller in Q2 2022 was Goldman Sachs, an estimated $100K sold.
Based on aggregated 13F filings for Q2 2022.